International experience of pregnancy outcomes in auto-inflammatory syndromes treated with Interleukin-1 inhibitors.

Many patients on anti-IL-1 therapy are unable to stop treatment prior to conception or during pregnancy but little data exist regarding safety. We report the outcomes of 20 IL-1 inhibitor exposed pregnancies in 18 women from 7 countries (including the first data on canakinumab exposed pregnancy) and paternal exposure to anakinra or canakinumab at conception.